CompBrief BY VELARION

Companies HilleVax, Inc.

HilleVax CEO salary & total pay, FY2024: $6.7M

HilleVax (HLVX) CEO salary, fiscal 2024: Robert Hershberg was paid a salary of $666,750 and $6,734,876 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me HilleVax, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Robert Hershberg's complete compensation dossier

A PDF and a CSV sent to your email: Robert Hershberg's pay in every fiscal year HilleVax, Inc. reported it, line by line, with Robert Hershberg's equity grants and HilleVax, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$6,734,876CEO Robert Hershberg · source

CEO pay, last three years

  • $9,697,495FY2023
  • $6,734,876FY2024

CEO total pay was $6,734,876 in fiscal 2024, down from $9,697,495 in fiscal 2023.

FY2024: salary $666,750 · bonus $0 · stock awards $2,623,482 · option awards $3,416,888

Executives and directors

Frequently asked questions

Who was the highest-paid executive at HilleVax, Inc. in fiscal 2024?
As disclosed, Robert Hershberg (Chairman, President and Chief Executive Officer) was the highest-paid executive at HilleVax, Inc. in fiscal 2024, with total compensation of $6,734,876.
How much does HilleVax, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, HilleVax, Inc. reported total board compensation of $377,802 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Robert Hershberg$666,750$0$2,623,482$3,416,888$0$0$27,756$6,734,876
Chairman, President and Chief Executive Officer
Sean McLoughlin450,000003,542,50000544,3154,536,815
Former Chief Operating Officer
Aditya Kohli500,0000826,7641,076,79000626,9773,030,531
Former Chief Business Officer and former Chief Operating Officer
Shane Maltbie473,0000715,681932,1240039,3752,160,180
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Robert Hershberg$6,734,876$9,697,495—↓ −2,962,619
Sean McLoughlin4,536,815———
Aditya Kohli3,030,5314,076,137—↓ −1,045,606
Shane Maltbie2,160,180———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The company's compensation program is designed to align the interests of employees and executive officers with those of stockholders. Equity-based incentive awards are the primary vehicle for long-term alignment, granted under the 2022 Incentive Award Plan to new hires and for ongoing employees.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Aditya KohliOption82,795—18—
Aditya KohliOption28,302—15.06—
Robert HershbergRSU—24,295—50,291
Robert HershbergRSU—140,975—291,818
Robert HershbergOption—175,06018—
Robert HershbergRSU—174,202—260,598
Robert HershbergOption—226,88515.06—
Sean McLoughlinOption98,958—14.17—
Shane MaltbieOption69,34123,1146.99—
Shane MaltbieOption11,5575,2538.05—
Shane MaltbieRSU—32,500—67,275
Shane MaltbieOption29,79135,20918—
Shane MaltbieRSU—47,522—98
Shane MaltbieOption—61,89415.06—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Patrick HeronIndependent · Audit · Nominating and Corporate Governance (Chair)$79,041—$309,375—$0$388,416
Julie Gerberding, M.D., M.P.HIndependent · Compensation (Chair) · Nominating and Corporate Governance63,962—309,375—0373,337
Nanette Cocero, Ph.DIndependent · Audit · Nominating and Corporate Governance59,464—309,375—0368,839
Shelley Chu, M.D., Ph.DIndependent · Compensation52,540—309,375—0361,915
Jaime Sepulveda, M.D., D.Sc., M.P.HIndependent · Nominating and Corporate Governance50,255—309,375—0359,630
Robert Hershberg, M.D., Ph.DEmployee director · Board Chair—————0
Aditya Kohli, Ph.DNot independent—————0
Gary Dubin, M.DNot independent0—0—00
Jeryl HillemanIndependent · Audit (Chair) · Compensation72,540—309,375—0—

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2024
Cash retainers and fees$377,802
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$377,802

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names HilleVax as a peer

Companies that benchmark against HLVX

No companies currently name HLVX as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1HilleVax, Inc.2024Robert Hershberg$666,750$2,623,482$3,416,888$0$6,734,876

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-23—————
20242024-06-06—————
20232023-06-07—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20252025-06-23—a
20242024-06-06—b
20232023-06-07—c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jeryl HillemanDirector2025-06-23A17,199$0$0CommonForm 4 ↗
Gary DubinDirector2025-06-23A17,19900CommonForm 4 ↗
Julie L. GerberdingDirector2025-06-23A17,19900CommonForm 4 ↗
Nanette CoceroDirector2025-06-23A17,19900CommonForm 4 ↗
Jaime SepulvedaDirector2025-06-23A17,19900CommonForm 4 ↗
Shelley ChuDirector2025-06-23A17,19900CommonForm 4 ↗
Aditya KohliDirector2025-06-23A17,19900CommonForm 4 ↗
Patrick HeronDirector2025-06-23A17,19900CommonForm 4 ↗
Jaime SepulvedaDirector2025-09-17D59,224——CommonForm 4 ↗
Shane MaltbieChief Financial Officer2025-09-17D83,738——CommonForm 4 ↗
Julie L. GerberdingDirector2025-09-17D59,224——CommonForm 4 ↗
Aditya KohliDirector2025-09-17D698,171——CommonForm 4 ↗
Gary DubinDirector2025-09-17D17,199——CommonForm 4 ↗
Shelley ChuDirector2025-09-17D17,199——CommonForm 4 ↗
Jeryl HillemanDirector2025-09-17D59,224——CommonForm 4 ↗
Robert HershbergDirector2025-09-17D1,101,498——CommonForm 4 ↗
Nanette CoceroDirector2025-09-17D17,199——CommonForm 4 ↗
Frazier Life Sciences X, L.P.Greater-than-10% holder2025-09-17D17,199233,538CommonForm 4 ↗
Frazier Life Sciences X, L.P.Greater-than-10% holder2025-09-17D8,535,337216,643,907CommonForm 4 ↗
TAKEDA PHARMACEUTICAL CO LTDGreater-than-10% holder2025-09-17D6,724,000213,111,800CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (39 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Robert Hershberg. DEF 14A, filed 2025-04-30. Section “Executive Compensation” · page 23. As printed: 6,734,876. View filing ↗
  • Section 01, Sean McLoughlin. DEF 14A, filed 2025-04-30. Section “Executive Compensation”. As printed: 4,536,815. View filing ↗
  • Section 01, Aditya Kohli. DEF 14A, filed 2025-04-30. Section “Executive Compensation”. As printed: 3,030,531. View filing ↗
  • Section 01, Shane Maltbie. DEF 14A, filed 2025-04-30. Section “Executive Compensation”. As printed: 2,160,180. View filing ↗
  • Section 08, Patrick Heron. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 388,416. View filing ↗
  • Section 08, Julie Gerberding, M.D., M.P.H. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 373,337. View filing ↗
  • Section 08, Nanette Cocero, Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 368,839. View filing ↗
  • Section 08, Shelley Chu, M.D., Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 361,915. View filing ↗
  • Section 08, Jaime Sepulveda, M.D., D.Sc., M.P.H. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 359,630. View filing ↗
  • Section 08, Robert Hershberg, M.D., Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Aditya Kohli, Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Gary Dubin, M.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Jeryl Hilleman. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: —. View filing ↗
  • Section 02, Jeryl Hilleman 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gary Dubin 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Julie L. Gerberding 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nanette Cocero 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jaime Sepulveda 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shelley Chu 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aditya Kohli 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Patrick Heron 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jaime Sepulveda 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Maltbie 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Julie L. Gerberding 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aditya Kohli 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gary Dubin 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shelley Chu 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeryl Hilleman 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert Hershberg 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nanette Cocero 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frazier Life Sciences X, L.P. 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frazier Life Sciences X, L.P. 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, TAKEDA PHARMACEUTICAL CO LTD 2025-09-17. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-10. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-13. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 377,802 + equity 0 + all other 0 = 377,802, summed across the director compensation table rows.
  • HilleVax, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-30. CEO total compensation as printed in HilleVax, Inc.'s own proxy. As printed: 6,734,876. View filing ↗
Get the full report — $299